A novel non-canonical Wnt signature for prostate cancer aggressiveness by Sandsmark, Elise et al.
Oncotarget1www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Advance Publications 2016
A novel non-canonical Wnt signature for prostate cancer 
aggressiveness
Elise Sandsmark1, Ailin Falkmo Hansen1, Kirsten M. Selnæs1, Helena Bertilsson2,3, 
Anna M. Bofin4, Alan J. Wright5, Trond Viset6, Elin Richardsen7,8, Finn Drabløs3, 
Tone F. Bathen1, May-Britt Tessem1,*, Morten B. Rye2,3,9,*
1Department of Circulation and Medical Imaging, Faculty of Medicine, NTNU - Norwegian University of Science and Technology, 
Trondheim, Norway
2Department of Urology, St. Olavs Hospital, Trondheim University Hospital, Norway
3Department of Cancer Research and Molecular Medicine, Faculty of Medicine, NTNU - Norwegian University of Science and 
Technology, Trondheim, Norway
4Department of Laboratory Medicine, Children’s and Women’s Health, Faculty of Medicine, NTNU - Norwegian University of 
Science and Technology, Trondheim, Norway
5Cancer Research UK Cambridge Institute, University of Cambridge, United Kingdom
6Department of Pathology and Medical Genetics, St. Olavs Hospital, Trondheim University Hospital, Norway
7Department of Medical Biology, UiT - The Arctic University of Norway, Tromsø, Norway
8Department of Clinical Pathology, University Hospital of North Norway, Tromsø, Norway
9St. Olavs Hospital, Trondheim University Hospital, Norway
*These authors have contributed equally to this work
Correspondence to: Elise Sandsmark, email: elise.sandsmark@gmail.com
Morten B. Rye, email: morten.rye@ntnu.no
Keywords: EMT, gene expression signature, biochemical recurrence, spectroscopy, MRSI
Received: August 26, 2016    Accepted: November 23, 2016    Published: December 24, 2016
ABSTRACT
Activation of the Canonical Wnt pathway (CWP) has been linked to advanced 
and metastatic prostate cancer, whereas the Wnt5a-induced non-canonical Wnt 
pathway (NCWP) has been associated with both good and poor prognosis. A newly 
discovered NCWP, Wnt5/Fzd2, has been shown to induce epithelial-to-mesenchymal 
transition (EMT) in cancers, but has not been investigated in prostate cancer. The aim 
of this study was to investigate if the CWP and NCWP, in combination with EMT, are 
associated with metabolic alterations, aggressive disease and biochemical recurrence 
in prostate cancer. An initial analysis was performed using integrated transcriptomics, 
ex vivo and in vivo metabolomics, and histopathology of prostatectomy samples 
(n=129), combined with at least five-year follow-up. This analysis detected increased 
activation of NCWP through Wnt5a/ Fzd2 as the most common mode of Wnt activation 
in prostate cancer. This activation was associated with increased expression of EMT 
markers and higher Gleason score. The transcriptional association between NCWP 
and EMT was confirmed in five other publicly available patient cohorts (1519 samples 
in total). A novel gene expression signature of concordant activation of NCWP and 
EMT (NCWP-EMT) was developed, and this signature was significantly associated 
with metastasis and shown to be a significant predictor of biochemical recurrence. 
The NCWP-EMT signature was also associated with decreased concentrations of the 
metabolites citrate and spermine, which have previously been linked to aggressive 
prostate cancer. Our results demonstrate the importance of NCWP and EMT in prostate 
cancer aggressiveness, suggest a novel gene signature for improved risk stratification, 
and give new molecular insight.
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INTRODUCTION
Increased activation of the Wnt signaling pathway 
(WP) is associated with development, progression, and 
metastasis of many cancers [1]. In prostate cancer, the WP 
has been associated with aggressive, late stage disease, 
and metastasis [2–5]; however, its potential for early 
prediction of aggressiveness is still unclear. Previous 
studies are mainly performed in prostate cancer cell lines 
[6–9], and proper validation in human tissue is lacking. 
The WP is proposed as a therapeutic target in prostate 
cancer treatment [10], and reduced proliferation has been 
detected as a result of targeted Wnt-inhibitor drugs in cell 
lines [11, 12]. However, to develop Wnt-targeted drugs for 
human prostate cancer, an increased understanding of the 
molecular mechanisms in vivo is needed.
Wnt ligands bind to Frizzled (Fzd) receptors to 
activate the WP, which then induces signal transduction 
cascades. The WP is generally divided into a β-catenin-
dependent canonical WP (CWP), and a β-catenin-
independent non-canonical WP (NCWP). The importance 
of the CWP in carcinogenesis was first discovered in 
colorectal cancer, where mutations of the APC gene, a 
part of the β-catenin destruction complex (Figure 1A), 
resulted in stabilization and nuclear translocation of 
β-catenin [13]. This β-catenin translocation is a hallmark 
of CWP activation, and can drive tumor invasion and 
metastasis through a process of epithelial-to-mesenchymal 
transition (EMT) [14]. During EMT, epithelial cancer cells 
develop into less adhesive and more motile mesenchymal-
like cells, which increases the cancer’s potential for 
invasion and metastasis [15]. There is mounting evidence 
associating EMT in prostate cancer with increased 
aggressiveness [16]. Several studies support the activation 
of CWP in advanced and metastatic prostate cancer [7, 
17], but little evidence exists for localized and locally 
advanced prostate cancer.
The NCWP is commonly divided into two pathways, 
the planar cell polarity (PCP), and the Wnt/Calcium 
pathway (Figure 1B-1C). Few studies have addressed the 
significance of NCWP in prostate cancer. Most attention 
has been focused on the role of the non-canonical ligand 
Wnt5a, a key activator of the NCWP. Wnt5a is generally 
found to be upregulated in prostate cancer, but results are 
inconsistent regarding its association with good [18–20] 
or poor prognosis [21]. Recently, a new NCWP involving 
Wnt5a and the receptor Frizzled2 (Fzd2) was discovered 
(Figure 1D) and shown to promote tumor progression and 
EMT in several cancer cell lines and a mouse xenograft 
model [22]. In the same study, a Wnt5/Fzd2 based gene 
set was also shown to accurately predict metastasis 
and survival in a small cohort (n=46) of patients with 
hepatocellular carcinoma. However, this study did not 
address the in vivo relevance of the NCWP in larger 
patient cohorts or in prostate cancer tissue.
Metabolic reprogramming is a hallmark of cancer 
[23], and the WP has been suggested as an emerging 
mediator of cancer cell metabolism [24, 25]. Wnt5a-
mediated NCWP has been directly related to alterations 
of the energy metabolism in melanoma and breast cancer 
cells [26]. Selected metabolic alterations detected in 
tissue samples by high resolution magic angle spinning 
magnetic resonance spectroscopy (HR-MAS MRS) can 
be translated for use in a clinical setting by magnetic 
resonance spectroscopy imaging (MRSI). Differences 
in (choline + creatine + spermine)/citrate ratio between 
Figure 1: Schematics of Wnt signaling pathways in cancer cells. A. Canonical Wnt pathway. In the absence of Wnt signaling, the 
β-catenin destruction complex labels β-catenin for proteasomal degradation. In the presence of Wnt signaling, the destruction complex is 
inhibited, resulting in stabilization and nuclear translocation of β-catenin, activating transcription of target genes. B. Non-canonical planar 
cell polarity (PCP) pathway activates signaling cascades resulting in cytoskeletal changes, as well as alterations in cell polarity, movement 
and survival. C. Non-canonical Wnt/Calcium pathway signaling activates intracellular calcium, which in turn reduce cell adhesion through 
further signaling. D. Non-canonical Wnt5/Fzd2 pathway. Wnt5 signals via the FZD2 receptor and FYN activates STAT3 transcription 
leading to epithelial-mesenchymal transition (EMT) in cancer cells.
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low and high histopathological Gleason score have 
previously been detected using in vivo MRSI of patients 
[27], and citrate and spermine are suggested as the main 
contributors to discriminating on the basis of tumor 
aggressiveness from tissue HR-MAS MRS analysis [28]. 
To date, metabolic alterations associated with the WP have 
not been investigated in prostate cancer.
The aim of this study was to investigate if the 
CWP and NCWP, in combination with EMT markers, 
are activated and associated with aggressive disease and 
metabolic alterations in human prostate cancer. To approach 
these questions, we first used a patient cohort where 
integrated omics analyses were performed on the same 
samples from fresh-frozen prostatectomy-tissue slices, 
including transcriptomics, tissue ex vivo and in vivo patient 
metabolomics, and detailed histopathological evaluation 
[29]. Histopathology allowed us to control for tissue 
heterogeneity, particularly the fraction of stroma, which is 
a major complicating factor when analyzing tissue samples 
[30]. The findings were confirmed in publicly available 
prostate cancer cohorts (n=1519 samples in total), and in 
a separate immunohistochemistry cohort. The analysis 
suggests that the NCWP, and not the CWP, is the most 
active WP for in vivo prostate cancer, and that this activity 
correlates with markers for EMT. Our approach allowed for 
the development of a novel NCWP-EMT gene signature 
significantly associated with recurrent and metastatic 
cancer and metabolic biomarkers. This signature may help 
differentiate aggressive from indolent prostate cancer.
RESULTS AND DISCUSSION
Patient and sample characteristics of the main and 
the immunohistochemistry cohorts are presented in Table 
1. The five validation cohorts (in total 1519 samples) are 
presented in the methods section with more information 
listed in Supplementary Table S1.
The canonical Wnt pathway is not activated in 
prostate cancer
To investigate if the CWP is activated in prostate 
cancer, we compared gene expression of the central CWP 
genes between cancer and normal samples of the main 
cohort using sample subsets balanced and unbalanced for 
stroma content according to histopathology (Figure 2A, 
Supplementary Table S2, Methods). The level of β-catenin 
(CTNNB1), the key component of the CWP pathway, 
showed no significant altered expression in cancer 
compared to normal, and two of the main components of 
the β-catenin destruction complex, GSK3B and AXIN1, 
were significantly upregulated in cancer. This may suggest 
increased activity of β-catenin destruction in prostate 
cancer, contrary to what is expected when the CWP is 
turned on. Additionally, the Wnt ligand genes associated 
with the CWP were not significantly changed in cancer 
compared to normal samples. Other important findings 
are reduced expression of the receptor FZD1, increased 
expressions of the antagonist SFRP4 and casein kinase 
CSNK1E, which support the absence of CWP activation. 
Although some variations were observed (Figure 2A), 
the lack of upregulation of the main CWP genes suggests 
no increased expression activity of the CWP in prostate 
cancer in our main cohort.
Translocation of β-catenin from the membrane 
to the nucleus is the hallmark of CWP activation, 
and to validate the findings above, we performed 
β-catenin immunohistochemistry (IHC) on the 
immunohistochemistry cohort (Figure 3A-3B). All the 
samples (n=40) had weak or non-detectable nuclear 
staining (SI≤2). Most of the samples (n=30) had strong 
membranous β-catenin staining (SI=9), indicating 
no activation of the CWP. Ten samples had weak or 
moderate membranous staining (SI≤6), indicating reduced 
membranous expression without increased nuclear 
expression of β-catenin. These findings demonstrate 
that the CWP is not activated in prostate cancer in our 
immunohistochemistry cohort, which is in concordance 
with the gene expression results from the main cohort. 
We therefore conclude that there is little evidence of CWP 
activation in prostate cancer compared to normal prostate 
tissue investigated in two independent cohorts.
We further investigated alterations in the CWP 
between low Gleason (≤3+4) and high Gleason (≥4+3) 
samples (Figure 2A). There were no significant gene 
expression alterations detected for β-catenin (CTNNB1), 
the Wnt ligands, the receptor-complex and the destruction 
complex (Supplementary Table S2). Of the CWP 
inhibitors, both SFRP2 and SFRP4 were upregulated in 
high Gleason compared to low Gleason cancer samples, 
which is contradictory to CWP activation. However, the 
inhibitor of β-catenin translocation, ICAT (CTNNBIP1), 
was downregulated, and the CWP transcription factors 
LEF1 and TCF were upregulated in high Gleason 
cancer, which could indicate activation of downstream 
components of the pathway independently of the β-catenin 
destruction complex. To conclude, the overall analysis 
suggests no significant increase in CWP activation through 
the canonical destruction complex, neither in cancer 
compared to normal nor in high Gleason cancer.
There is currently no consensus in the literature 
regarding CWP activation in prostate cancer, and our 
findings are contradictory to several previous studies 
suggesting increased CWP in prostate cancer [7, 9, 17]. 
The CWP has previously been associated with advanced 
disease such as androgen resistant prostate cancer in cell 
lines [7], and prostate cancer bone metastasis in human 
tissue and cell lines [8, 17]. The fact that our cohorts 
consist of radical prostatectomy tissue, from localized or 
locally advanced disease, may explain the absence of CWP 
activation. The CWP may therefore still be of importance 
in advanced, metastatic prostate cancer, but might not 
prove useful for early risk stratification. Furthermore, 
several previous studies reporting increased CWP signaling 
Oncotarget4www.impactjournals.com/oncotarget
were using prostate cancer cell lines [6–9]. The disparity 
could therefore also highlight a difference between in 
vitro cell lines and human prostate tissue, emphasizing the 
importance of validation studies in human tissue, especially 
for identification of potential targets for personalized drug 
therapy.
In our main cohort, the central CWP genes showed 
an expression pattern that was indicative of substantial 
stromal influence when comparing normal against cancer 
tissue (Figure 2A). This trend was particularly strong for 
genes that, directly or partly, regulate the activity of the 
β-catenin destruction complex, and indicates a difference 
of CWP activity when cancer is compared to stroma, but 
not when compared to benign epithelium. Thus, at least 
some of the discrepancies from previous studies of CWP 
in prostate cancer may be explained by uneven sampling 
of stroma content between cancer and normal samples 
which has previously been observed in tissue samples 
from prostate cancer patient cohorts [30, 31].
Wnt5a-induced non-canonical Wnt signaling is 
increased in high Gleason prostate cancer
The NCWP, including the Wnt/Calcium, PCP and 
the new Wnt5/Fzd2 pathways, were investigated (Figure 
2B, Supplementary Table S2). When comparing cancer 
with normal samples, we found no alterations in any of 
the pathway components apart from downregulation of the 
ligand WNT5B, and upregulation of the calcium pathway 
component PLCB2, suggesting no increased activation 
of the NCWP in prostate cancer in general. However, 
when high Gleason samples were compared with low 
Gleason samples, significantly increased expressions were 
detected for three of the four key genes of the Wnt5/Fzd2 
pathway; the ligand WNT5A (p<0.001), the receptor FZD2 
(p=0.003) and the midstream kinase component FYN 
(p<0.001) (Figure 2B). No significant expression change 
was detected for the last key component, the transcription 
factor STAT3. For the Wnt/Calcium pathway, only PLCB2 
was upregulated in high Gleason cancer (Figure 2B), and 
none of the central components of the PCP pathway were 
altered (Supplementary Table S2). In summary, these data 
suggest upregulation of the Wnt5/Fzd2 pathway in high 
Gleason prostate cancer.
For validation, IHC of WNT5A was performed 
on the immunohistochemistry cohort (Figure 3C-3D). 
Of the 40 cancer samples, 32 had strong (SI=9) and 
8 had moderate or weak staining (SI≤6). There was no 
association between the staining intensity and Gleason 
grade for this cohort.
Wnt5a has been suggested as a biomarker in prostate 
cancer, but its prognostic outcome has been inconsistent 
[18–21]. The increased WNT5A gene expression in high 
Gleason cancer samples compared to low Gleason samples 
Table 1: Patients and sample characteristics of the two cohorts
 Main cohort Immunohistochemistry cohort
Patients  n=41 n=40
Age (median, range) Years 64 (48-69) 62 (48-73)
sPSA (median, range) Before Surgery (ng/mL) 9.1 (4.0-45.8) 8.9 (5.2-18.0)
Clinical pT stage (patients) pT1c - 7
 pT2 28 20
 pT3 13 10
 Unknown - 3
    
Tissue samples  n=129 n=40
Sample weight (mean, range) (mg) 12.7 (3.0-21.9) 12.6 (7.6-21.0)
Gleason score of tissue samples
Benign 34 - *
6 24 5
 7 41 25
 8 15 5
 9 15 4
 10 - 1
Gleason grade groups Low Gleason (≤3+4) 48 21
 High Gleason (≥4+3) 47 19
* 50 benign samples were excluded from further analysis in the immunohistochemistry cohort
sPSA – serum PSA, pT stage – pathological tumor stage.
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Figure 2: Alterations in central Wnt and EMT genes 
in prostate cancer compared with normal samples 
(balanced for stroma), high Gleason compared with 
low Gleason prostate cancer, and high stroma content 
compared with low stroma content (unbalanced) tissue 
samples. The x-axis displays log10(p-value) fold change, 
multiplied by −1 for upregulated genes, and 1 for downregulated 
genes. P-values for prostate cancer vs. normal prostate tissue are 
balanced for stroma content; unbalanced p-values are available in 
Supplementary Table S2. A. The central canonical genes show a 
pattern of no further activation in cancer or high Gleason cancer, 
but show a confounding stroma effect, especially of the genes of the 
destruction complex. B. The central non-canonical genes generally 
show an upregulation of Wnt5/Fzd2 genes in high Gleason cancer. 
C. The central epithelial-mesenchymal transition (EMT) positive 
genes indicate ongoing EMT, especially in high Gleason cancer. D. 
The central EMT negative genes.
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is in agreement with results from Yamamoto et al. who 
reported increased Wnt5a IHC staining of prostatectomy 
tissue samples with high Gleason grade [21]. This oncogenic 
effect of Wnt5a in prostate cancer progression is also 
supported by studies of cell lines, where Wnt5a has been 
shown to improve migration capacity [32], induce androgen 
resistance in prostate cancer metastases [33], and induce 
bone metastasis [8]. Contrary to this, other IHC studies 
of prostatectomy tissue samples have detected a tumor-
suppressing role of Wnt5a in prostate cancer; increased 
Wnt5a IHC expression has been associated with increased 
10 years survival [18], and a lower risk of biochemical 
recurrence [19, 20]. This was, however, only true for low 
Gleason grade samples in one of the studies [20]. This 
apparent opposing role of Wnt5a in prostate cancer may 
be explained by the paradoxical effect of Wnt5a in other 
cancers. In melanoma, pancreatic and gastric cancer, Wnt5a 
expression is associated with worse prognosis, but in colon 
and thyroid cancer Wnt5a expression is associated with 
better prognosis as reviewed by McDonald and Silver, and 
Zhu et al. [34, 35]. The tumor-promoting role of Wnt5a can 
be caused by activation of NCWP [35], whereas the tumor-
suppressing role may be caused by inhibition of the CWP 
[36]. Because of this conflicting role in different cancer 
types, we suspect that Wnt5a alone may not be a useful 
biomarker for prostate cancer.
EMT markers are upregulated in high Gleason 
prostate cancer
The Wnt5/Fzd2 NCWP has previously been linked 
with EMT studies on various cancer cell-lines, but not 
in prostate cancer [22]. We therefore evaluated the gene 
expression of the most central EMT positive and negative 
markers in prostate cancer in the main cohort (Figure 2C 
and 2D). When comparing high Gleason with low Gleason 
samples, significant upregulations were detected for the 
expression of EMT positive markers in high Gleason; 
N-cadherin (CDH2), OB-cadherin (CDH11), vimentin 
(VIM) and Delta-2-catenin (CTNND2) (Figure 2C). In 
addition, a non-significant downregulation of E-cadherin 
(CDH1), an EMT negative marker, was observed in high 
Gleason samples (fold-change=-0.25, p=0.07; Figure 
2D), suggesting ongoing EMT in high Gleason samples. 
In the immunohistochemistry cohort, IHC of N-cadherin 
showed membranous staining (SI≥2) in only two, both 
high Gleason, of the forty cancer samples (Figure 3E-3F). 
Reduced, moderate membranous staining of E-cadherin 
(SI=6), was detected in five samples while the remaining 
samples had strong membranous staining (SI=9) (Figure 
3G-3H). However, the reduced E-cadherin staining did 
not correspond to N-cadherin staining, as hypothesized 
for the N- to E-cadherin switch proposed to be important 
for EMT in prostate cancer [37]. Inspection of the 
principal component analysis (PCA) score plots for the 
main and validation cohorts also confirmed consistent 
N-cadherin upregulation correlating with high Gleason 
and EMT genes, while the anticorrelation to E-cadherin 
was inconsistent between the cohorts, in accordance with 
observations in the immunohistochemistry cohort (Figure 
4A, 4C-4G). In conclusion, the increased levels of several 
EMT positive genes, suggests ongoing EMT in a subset 
of mainly high Gleason prostate cancer samples. This 
was partly supported by the IHC, although the number of 
samples in the immunohistochemistry cohort was too few 
to make a conclusion.
Figure 3: Immunohistochemical staining of the 
immunohistochemistry cohort. A. Strong membranous 
β-catenin staining and B. weak β-catenin staining. C. Strong 
Wnt5a staining and D. weak Wnt5a staining. E. Positive 
membranous N-cadherin staining and F. negative N-cadherin 
staining. G. Strong membranous E-cadherin staining and H. 
weak E-cadherin staining. Magnification x400. Bar 50μm. 
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A novel 15 gene non-canonical Wnt pathway - 
EMT (NCWP-EMT) signature
To further investigate the relationship between the 
expression of Wnt and EMT genes, PCA analysis was 
performed on the expression profiles of 48 central Wnt and 
EMT genes (Methods). The first two principal components 
clearly highlighted a separate cluster of 15 genes related 
to the Wnt5a/Fzd2 pathway and EMT (Figure 4A). This 
gene set included 11 genes, which were also upregulated 
in high Gleason samples. In addition, two inhibitors of the 
CWP (NKD2 and SFRP1), and two EMT positive markers 
(CDH3 and MMP9) were part of the PCA cluster and 
included in the gene set. Because of the clear relationship 
to Wnt5/Fzd2 NCWP and EMT, we will refer to this set of 
genes collectively as the NCWP-EMT genes.
Using all cancer samples in the main cohort, we 
calculated an average Pearson’s correlation r of 0.34 
between all 15 gene using pairwise correlations. This is 
comparable or higher than the average correlation between 
genes in previously validated prostate cancer signatures [38, 
39] (Figure 4B), including signatures for the established 
TMPRSS2-ERG gene fusion (average Pearson’s r=0.30). 
The pattern of the NCWP-EMT gene set from the main 
cohort was validated in PCA analysis of the Wnt-genes 
in the five publicly available cohorts (n=1519 samples in 
total, Supplementary Table S1). The same 48 central Wnt-
genes, in addition to WNT1, WNT3 and WNT3A which were 
lacking data in the main cohort, were used. All cohorts 
confirm the NCWP-EMT component as the most important 
source of variation in the gene expression, although there 
were some variations in the highlighted genes (Figure 4C-
4G and Supplementary Figure S1). The CWP was either 
insignificant or spanning a separate axis of variation with 
little correlation to EMT. Interestingly, WNT5A expression 
pattern varied considerably with respect to the NCWP-EMT 
axis. Overall, these data show the NCWP-EMT gene cluster 
to be robust over large prostate cancer patient cohorts, and 
the 15 NCWP-EMT genes to be accessible for a concordant 
NCWP-EMT gene expression signature.
The continuous single sample gene set enrichment 
analysis (GSEA) score of the novel NCWP-EMT signature 
was significantly correlated with the Gleason score of the 
samples (Pearson’s r of 0.49, p<0.001). When the samples 
were categorized according to the NCWP-EMT score as 
low, intermediate, and high, the distribution of low/high 
Gleason samples in the groups were as following: NCWP-
EMT low (n=25/n=7), NCWP-EMT intermediate (n=17/
n=14), and NCWP-EMT high (n=6/n=26). As expected 
most samples with high NCWP-EMT score also were 
high Gleason samples; however, some samples were low 
Gleason, and vice versa for samples with low NCWP-EMT 
score. This indicates that the NCWP-EMT signature might 
add an additional dimension for stratification, compared 
to Gleason grade alone. The NCWP-EMT signature may 
therefore, with further refinements and validation, be a 
useful addition to the selection criteria for active surveillance 
in prostate cancer patients.
The novel NCWP-EMT signature also showed 
significant association with previously published 
mesenchyme and cytokine gene signatures (Supplementary 
Figure S2), and highly significant gene ontology (GO) 
terms related to cell adhesion, extracellular matrix, 
inflammation and immune response which are features 
commonly associated with EMT (Supplementary Table 
S3). The same analysis based on the expression level of 
WNT5A alone, did not produce any significant GO terms, 
further supporting the hypothesis that Wnt5a alone is an 
ambiguous biomarker in prostate cancer.
The NCWP-EMT gene signature is associated 
with metabolic alterations
We further investigated the metabolic alterations of 
23 metabolites between samples with low, intermediate, 
and high activation of the developed NCWP-EMT 
gene expression signature (Supplementary Table S4) in 
the main cohort. The most prominent alterations were 
observed for the metabolites citrate and the polyamine 
spermine (Table 2), which showed significantly decreased 
concentration in the high NCWP-EMT compared to 
low NCWP-EMT samples. This alteration was also 
observed for high NCWP-EMT samples when compared 
with intermediate NCWP-EMT samples, but not when 
comparing intermediate with low NCWP-EMT samples. 
This suggests citrate and spermine alterations to be more 
profound in the samples with high NCWP-EMT score 
compared to low and intermediate score NCWP-EMT. 
In addition, there were alterations in the concentration of 
phosphoethanolamine and taurine between the low and the 
intermediate score group (p=0.002, p=0.028 respectively).
Decreased concentrations of citrate and spermine 
have been associated with aggressive prostate cancer [28, 
40], and our results therefore suggest the NCWP-EMT 
signature to be associated with an aggressive metabolic 
profile. Reduced citrate can be a result of increased energy 
production through the Krebs cycle in prostate cancer 
[41]. Previously, Wnt5a signaling has been identified as a 
regulator of the energy metabolism in melanoma cancer 
cells [26], and alterations of this metabolism have also 
been associated with EMT in cancer [42]. Another study 
detected that reduced polyamine content promoted EMT 
in non-tumor MDCK cells [43]. We therefore hypothesize 
that NCWP-EMT activation is associated with alterations in 
citrate and spermine metabolism in prostate cancer, although 
the direct mechanisms require further investigation.
To investigate the potential clinical translation of the 
metabolic findings, we inspected the gene signature score 
with matched pre-surgical in vivo MRSI from the same 
patients. Reduced citrate/creatine and spermine/creatine 
ratios were detected for high NCWP-EMT score samples 
when compared with low NCWP-EMT score (Table 2). 
Although we had a limited number of matched samples 
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Figure 4: The NCWP-EMT gene expression signature. A. Two component PCA plot reveals a group of 15 of 48 genes, mainly 
connected to Wnt5a/Fzd2 non-canonical Wnt pathway, epithelial-mesenchymal transition (EMT), and inhibitors of the canonical Wnt 
pathway, collectively termed NCWP-EMT (CDH2, CDH3, CDH11, FYN, FZD2, LEF1, MMP9, NKD2, PLCB2, SFRP1, SFRP2, SFRP4, 
VIM, TCF4 WNT5A). B. The Pearson correlation of co-expression of the genes in the NCWP-EMT signature is as good or better compared 
with other recognized genes expression signatures in prostate cancer. Random marks 200 randomly selected genes for validation. C-G. The 
NCWP-EMT signature confirmed in the validation cohorts, although there were some variations in the highlighted genes. High-resolution 
versions of the PCA plots including all gene names, and Pearson correlation of the validation cohorts are available in Supplementary Figure 
S1.
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in the main cohort (n=22), the results support our findings 
from the tissue analysis, and demonstrates that the MR 
biomarkers can reflect the NCWP-EMT signature also in 
non-invasive MRSI examinations.
Citrate and spermine are stored within the luminal 
space of the glands in prostate tissue, and the observed 
metabolic alterations can be due to cell metabolism or 
morphological changes. In the main cohort, the citrate 
and spermine concentrations were correlated with luminal 
space (Spearman’s rho=0.30/p=0.003, rho=0.31/p=0.003, 
respectively). This was a weaker correlation than between 
citrate and spermine concentrations and the NCWP-EMT 
signature score (Spearman’s rho=0.42/p<0.001, rho=0.38/
p<0.001, respectively). LMM, adjusting for luminal space 
as well as other tissue heterogeneity and Gleason score, 
still showed the same metabolic alterations to be significant 
(Supplementary Table S5). These results suggest the 
alterations observed in citrate and spermine concentrations 
are a combination of changes in both luminal space and 
reprogramming of metabolism in samples with high 
NCWP-EMT score. There was no relationship between 
Wnt5a expression and metabolite concentrations in either 
the main or immunohistochemistry cohort (Supplementary 
Table S6). This supports that Wnt5a should be used as a 
biomarker in combination with other pathway components, 
such as our NCWP-EMT signature.
NCWP-EMT signature may help predict 
biochemical recurrence
In the main cohort the five-year biochemical 
recurrence free rates were 100%, 75% and 46% for 
the patients in the low, intermediate and high NCWP-
EMT score groups, respectively, and the Kaplan-Meier 
plot showed a significant separation between the groups 
(log-rank p=0.035) (Figure 5A). Validation of recurrence 
was possible in the GSE21034 cohort (131 samples, 
27 with recurrence), and showed a similar pattern with 
10-year biochemical recurrence free rates of 81%, 73% 
and 57% in patients with low, intermediate and high 
NCWP-EMT score, respectively. However, there was 
no significant separation in the Kaplan-Meier curves 
for this cohort (log-rank p=0.522) (Figure 5B). For this 
validation dataset there was only one sample per patient, 
not necessarily extracted from the most aggressive cancer 
foci, which may reduce the precision of the NCWP-EMT 
grouping for biochemical recurrence analysis. In addition, 
many of the patients in the validation dataset were lost to 
follow-up early, and therefore censored in the analysis 
(Figure 5B), causing reduces reliability of the curves. In 
the GSE46691 cohort, samples with high NCWP-EMT 
scores were significantly associated with metastases 
(545 samples, 212 with metastasis, p-value<0.001, 
chi-square test, Supplementary Figure S3). With the 
significant separation in our data, and the similar trend 
in the validation datasets, we therefore suggest that 
increased NCWP-EMT signature score is associated 
with an increased risk of biochemical recurrence and 
metastases. This strengthens the NCWP-EMT signature, 
and the activation of the Wnt5/Fzd2 pathway, as markers 
of aggressive prostate cancer.
Patients in the main cohort with a post-operative 
Gleason score of 7 showed a five-year biochemical 
recurrence free survival of 100%, 89% and 67% with low, 
intermediate and high NCWP-EMT score, respectively 
(Figure 5C). Although not statistically significant, possibly 
due to the low number of patients (n=23), this separation 
with no crossing indicates that the NCWP-EMT gene 
Table 2: Alterations in citrate and spermine metabolism
Metabolite concentration (mmol/kg wet weight) ex vivo and 
metabolites amount/ratios in vivo p-values
a





 Median (IQR) Median (IQR) Median (IQR)    
Ex vivo (n=95) (n=32) (n=31) (n=32)  
Citrate 7.31 (5.57-11.56) 6.38 (4.56-11.58) 3.55 (2.08-7.25) 3.38·10-4* 0.018* 0.282
Spermine 1.55 (1.02-2.36) 1.23 (0.67-2.27) 0.75 (0.39-1.43) 3.38·10-4* 0.028* 0.113
 
In vivo (n=22) (n=10) (n=7) (n=5)  
Citrate/Creatine 7.36 (5.81-8.79) 4.45 (3.34-7.79) 2.77 (1.48-3.00) 0.0056* 0.027* 0.030*
Spermine/
Creatine 0.83 (0.44-1.04) 0.50 (0.04-1.11) 0.00 (0.00-0.02) 0.0057* 0.027* 0.101
IQR – Interquartile range
* Indicates significance at p<0.05
a P-values from LMM adjusting for multiple samples per patient, and corrected for multiple testing by Benjamini and 
Hochberg procedure.
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signature might be useful for improved risk stratification 
in the challenging group of patients with Gleason score 7.
Univariate cox proportional hazards analyses 
identified NCWP-EMT, Gleason score and pathological 
T-stage as significant predictors of biochemical 
recurrence (Table 3). Multivariate analysis showed 
both NCWP-EMT and post-operative Gleason score 
to be significant predictors of biochemical recurrence 
(Table 3). The multivariate model included a significant 
interaction term between NCWP-EMT and post-
operative Gleason score, implying that the hazards 
ratio of these variables were dependent on the value of 
the other variable. For patient with low post-operative 
Gleason score (≤ 7), the hazard ratio for NCWP-
EMT was 1.61, indicating that increased NCWP-
EMT signature score gives a significant higher risk 
of biochemical recurrence for this group. To compare 
the NCWP-EMT and post-operative Gleason score as 
predictors of biochemical recurrence, two additional 
Cox proportional hazards models, each excluding either 
NCWP-EMT or post-operative Gleason score, were 
tested (Supplementary Table S8). The Akaike information 
criterion (AIC) represent the goodness of fit as well 
as the complexity of the model, and can be compared 
between models, where the lower AIC provides a better 
model fit. The model including post-operative Gleason 
Figure 5: Kaplan-Meier and ROC curves of biochemical recurrence. A. The main cohort shows clear separation in biochemical 
recurrence free survival between the low, intermediate and high NCWP-EMT signature groups. B. A validation cohort (GSE21034) shows 
the same pattern, although not a significant separation. C. A similar pattern was also shown for the patient of the main cohort with a post-
operative Gleason score of 7. D. The ROC curves of biochemical recurrence after 5 years show the same AUC of post-operative Gleason 
score and NCWP-EMT, but an increased AUC when combined. Δ Continuous NCWP-EMT signature score, * continuous post-operative 
Gleason score. Abbreviations: BCR - biochemical recurrence, RP – radical prostatectomy, ROC – Receiver operating characteristic, and 
AUC – area under the curve.
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had a slightly lower AIC (AIC=64.24) compared to the 
model including NCWP-EMT (AIC=65.61), suggesting 
post-operative Gleason to be a slightly better predictor 
of biochemical recurrence than NCWP-EMT. However, 
the model containing all variables, had the lowest AIC 
(AIC=60.15) demonstrating improved prediction of 
biochemical recurrence when NCWP-EMT and post-
operative Gleason score were modelled together.
Similar findings were also visualized by using 
logistic regression and receiver operating characteristic 
(ROC) curves with the depended variable being 
biochemical recurrence after 5-year follow-up. The 
area under the curve (AUC) of the ROC-curve were 
the same for NCWP-EMT and post-operative Gleason 
score (AUC=80.9), and in combination they provided 
increased sensitivity and specificity (AUC=90.4) (Figure 
5D). In conclusion, our results suggest that the NCWP-
EMT signature could be a useful addition in prediction of 
biochemical recurrence in prostate cancer.
CONCLUSIONS
The present study showed no alterations in the CWP 
in prostate cancer, but revealed an increased expression of 
NCWP and EMT markers in a subgroup of mainly high 
Gleason grade prostate cancer samples. A novel gene 
expression signature (NCWP-EMT) for this expression 
profile was presented and confirmed in several publicly 
available patient cohorts. High NCWP-EMT score was 
associated with reduced concentrations of the metabolites 
citrate and spermine both ex vivo, and in a clinical non-
invasive setting using in vivo patient MRSI. The novel 
NCWP-EMT signature was also shown to be a predictor 
of biochemical recurrence and was associated with 
metastasis, indicating that upregulation of the NCWP and 
EMT is linked to more aggressive prostate cancer. The 
novel NCWP-EMT signature may therefore be useful 
for risk stratification and molecular subtyping of prostate 
cancer patients. The NCWP and its relation to EMT, 
cancer aggressiveness and tumor metabolism warrants 
further attention in prostate cancer studies.
MATERIALS AND METHODS
Patients and tissue samples
In the main cohort, human prostate tissue was 
collected from 41 localized and locally advanced prostate 
cancer patients. The tissue harvesting was performed on 
fresh-frozen prostatectomy specimens using a standardized 
method thoroughly described by Bertilsson et al. [29]. A 
total of 95 cancer tissue samples, and 34 adjacent normal 
tissue samples were collected (median 3, range 1-6 samples 
per patient). At least five years of follow-up data were 
successfully retrieved for 33 patients in the main cohort, 
including the date of biochemical recurrence (PSA of at 
least 0.2 ng/mL) and/or last negative PSA measurement. 
To validate the results of the main cohort, an additional 
Table 3: Univariate and multivariate Cox proportional hazards analyses of biochemical recurrence







































Post-operative Gleason score (≤7Δ and ≥8)
(interaction term)
- - 0.37(0.18-0.74) 0.005*
Δ Indicates the category used as a reference in each analysis.
* Indicates significant p-value.
Low GS – Hazard ratio/p-value for patients with post-operative Gleason score ≤7
High GS – Hazard ratio/p-value for patients with post-operative Gleason score ≥8
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cohort of 90 needle biopsies from 90 localized and locally 
advanced cancer patients were harvested and snap frozen 
within seconds after prostatectomy. Of these, only the 
samples with histopathological confirmed cancer were used 
as the immunohistochemistry cohort for this study (n=40). 
The patients in both cohorts received no prostate cancer 
treatment prior to surgery and had no detected metastasis 
at diagnosis. The Regional Committee of Medical and 
Health Research Ethics (REC), Central Norway approve 
both cohorts, and all patients gave written, informed 
consent. Validation was performed in four prostate cancer 
microarray datasets available through the Gene Expression 
Omnibus with GEO accessions GSE8218 (65 samples) 
[44], GSE16560 (281 samples) [45], GSE21034 (131 
samples) [46], GSE46691 (545 samples) [47], and one 
data set from The Cancer Genome Atlas (TCGA, 497 
samples) [48], in total 1519 samples (Supplementary Table 
S1). These datasets are collectively termed the validation 
cohorts. Biochemical recurrence was validated in the 
GSE21034 cohort, and metastasis in the GSE46691 cohort.
Histopathology
In the main cohort, tissue slices for histopathological 
evaluation were cryosectioned from each tissue sample 
prior to HR-MAS MRS [29]. All cryosections were stained 
with Haematoxylin and Eosin, and the histopathological 
evaluations were performed according to the clinical 
criteria for prostate cancer, by an experienced pathologist 
specialized in uropathology (TV). The percentage of 
Gleason grades, cancer, normal glandular epithelia, 
and stromal tissue were reported for each sample. 
Reproducibility of the histopathological scoring was 
assessed independently by a second pathologist specialized 
in uropathology (ER), and the overall kappa (κ) coefficient 
for interobserver agreement of Gleason score was 0.66 
indicating substantial agreement. The first reading was used 
in this study due to slight degradation of the cryosections 
between the readings (5 years, slides kept dry and dark). 
Luminal space was quantified in each sample by a color-
based segmentation method (Positive Pixel Count algorithm 
in ImageScope v.8, Aperio Technologies) [49]. The samples 
in the immunohistochemistry cohort were formalin fixed 
and paraffin embedded for sectioning after HR-MAS 
MRS analysis, and histopathological evaluation was 
done according to the same protocol as the main cohort. 
In both cohorts, we investigated differences between low 
and high Gleason grade by sorting the tissue samples into 
two groups, where samples in the low Gleason group had a 
Gleason score ≤ 3+4 and samples in the high Gleason group 
had a Gleason score ≥ 4+3 (Table 1).
HR-MAS MRS and MRSI experiments and 
quantification
For both the main and the immunohistochemistry 
cohort, proton HR-MAS MRS was acquired using a 
Bruker Avance DRX600 Spectrometer (Bruker Biospin, 
Germany) equipped with a dual 1H/13C MAS probe. 
Absolute quantification of the spectra was performed 
using LCModel [50] with a basis set of 23 metabolites, 
and reported in mmol/kg wet weight. Full procedure 
and parameters of the HR-MAS MRS acquisition and 
LCModel quantification have earlier been described by 
Giskeødegård et al. [28]. In vivo patient MRSI examination 
of the prostate, performed using a 3T system (Magnetom 
Trio, Siemens, Germany) prior to prostatectomy, was 
available on a subset of the patients in the main cohort 
(n=9). Choline, citrate, creatine and spermine were 
quantified using LCModel, and creatine was used as an 
internal standard for normalization (metabolites to creatine 
ratios). HR-MAS cancer samples from the same patients 
were spatially matched to an in vivo voxel (n=22). Further 
details on the MRSI acquisition, quantification, and spatial 
matching are previously described by Selnæs et al. [27].
Gene expression, selection of genes, and 
controlling for confounding stroma
In the main cohort, gene expression analysis was 
performed after HR-MAS MRS on the exact same tissue 
sample, using an Illumina TotalPrep RNA Amplification 
Kit (Ambion Inc.) and an Illumina Human HT-12v4 
Expression Bead Chip (Illumina), as described by 
Bertilsson et al. [51]. The microarray data has previously 
been published in Array Expression with access number: 
E-MTAB-1041. Genes relevant to both the WP and EMT 
were carefully chosen by investigating literature and 
publicly available pathway maps (KEGG as per March 
2015) [2, 3, 5, 22]], resulting in 196 genes (Supplementary 
Table S2). To control for the effect of confounding stroma 
tissue when identifying differentially expressed genes, we 
used a recently published strategy of balancing the stroma 
content between sample groups [30]. This strategy makes 
it possible to separate molecular signals relevant to cancer 
from signals originating due to different stroma fractions 
between the sample groups. Briefly described, the strategy 
selects samples to ensure an equal average fraction of 
stroma tissue (according to histopathology) in each sample 
group termed a balanced differential expression analysis. 
In contrast, an unbalanced analysis is also performed to 
highlight differentially expressed gene due to different 
average fractions of stroma tissue.
Immunohistochemistry (IHC)
In the immunohistochemistry cohort, IHC was 
performed with mouse monoclonal antibodies against 
Wnt5a (Sigma-Aldrich, clone 3A4, dilution 1:50), 
N-cadherin (Dako, clone 6G11, dilution 1:30), and 
E-cadherin/NCH-38 (Dako, clone NCH-38, dilution 
1:100) and polyclonal rabbit antibodies against 
β-catenin/CTNNB1 (PRESTIGE antibodies Sigma, 
dilution 1:300). The sections were counter-stained with 
Oncotarget13www.impactjournals.com/oncotarget
Haematoxylin. Assessment was performed manually, and 
all the IHC sections were evaluated based on the average 
staining intensity (0-3) multiplied by the percentage of 
positive cancer cells (0-3), obtaining a total staining index 
(SI) (0-9). A SI of 0 was regarded as negative, 1-2 as weak 
positive staining; 3-6 as moderate, and 9 as strong positive 
staining (Supplementary Table S7). An experienced 
pathologist (AMB) validated the scoring.
Statistical analysis
The WP and EMT genes were compared for 
differential expression between normal and cancer samples, 
and between low and high Gleason samples by t-test. All 
the 196 genes were considered, but to ease data analysis 
and presentation a subgroup 48 key and/or significantly 
altered genes are presented as the central genes, however, 
a full table of the p-values is given in Supplementary Table 
S2. PCA was used to further investigate and visualize 
the unsupervised relationship between the expressions 
of these central WP and EMT genes. Based on the PCA 
score plot, a distinct set of genes was selected to make a 
gene expression signature termed NCWP-EMT. The co-
expression between the signature genes was investigated 
by Pearson’s correlation, and compared to other recognized 
gene expression signatures in prostate cancer. The distinct 
gene-signature pattern from PCA and Pearson’s correlation 
between signature genes were confirmed in the validation 
cohorts. Single sample GSEA was performed to give each 
of the cancer samples in the main and validation cohorts a 
score representing the expression of the genes in the NCWP-
EMT signature [52]. The samples in each cohort were sorted 
into three equal sized groups of low, intermediate, and high 
NCWP-EMT signature scores, where the high score group 
had the highest pathway activity. Features associated with 
NCWP-EMT were investigated by Gene Ontology (GO) 
using the Database for Annotation and Visualization and 
Integrated Discovery (DAVID). Biochemical recurrence 
free survival for the NCWP-EMT score groups were 
plotted by Kaplan-Meier curves and tested by log-rank 
test in the main and GSE21034 cohort, where for the 
individual patient’s highest NCWP-EMT score was used 
in the main cohort. The association between NCWP-EMT 
and metastasis in the GSE46691 cohort was tested using 
a contingency table and chi-squared test. Univariate and 
multivariate cox proportional hazards statistics were used 
to investigate the role of the NCWP-EMT signature in 
prediction of biochemical recurrence. Prior to analysis, 
post-operative Gleason score, pathological T-stage and 
pre-operative PSA were dichotomized (Table 3), and 
together with the continuous NCWP-EMT signature score 
selected for multivariate analysis. Biochemical recurrence 
at five-year follow-up was selected to plot ROC curves 
of NCWP-EMT score, post-operative Gleason score and 
both combined. Linear mixed model (LMM) was used to 
account for multiple samples per patient, when investigating 
the relationship between NCWP-EMT score groups and 
metabolite concentrations. The analyses were repeated 
with additional adjustment for Gleason grade, and tissue 
heterogeneity including the proportion of cancer, benign 
epithelium, stroma and luminal space in the individual 
tissue sample. The immunohistochemistry cohort consisted 
of one sample per patient, and t-test was used to investigate 
the association between IHC and metabolite concentrations. 
Prior to analysis, all metabolite values were log transformed 
to obtain normalized residuals, and p-values were corrected 
for multiple testing using Benjamini-Hochberg false 
discovery rate. P-values <0.05 were considered significant. 
The statistical analyses were performed in R (version 3.2.0, 
R Foundation for Statistical Computing).
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